Reglan Tardive Dyskinesia Settlement: Eligibility Criteria Explained

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

Legacy of Evidence-Based Health Information

The domain saturday-reviewdrugtrials.com has historically provided structured, publicly accessible health and science information, drawing on authoritative sources such as ClinicalTrials.gov, PubMed, and FDA data repositories. This foundation supported the generation of content focused on clinical trial data, drug safety analysis, and therapeutic outcomes for a broad audience. The established approach emphasized factual reporting on drug mechanisms, adverse events, and regulatory milestones, serving researchers and healthcare professionals seeking reliable intelligence. Transitioning from this general health context, a specific occupational exposure concern emerges regarding Reglan (metoclopramide) and its association with tardive dyskinesia. While the legacy domain addressed drug safety broadly, the focus now narrows to the practical implications for individuals who have used Reglan, particularly those in workplace or clinical settings where prolonged exposure may occur. The shift requires moving from population-level data analysis to individualized risk assessment, emphasizing the criteria for settlement eligibility in cases of alleged harm. This pivot retains the domain’s commitment to evidence-based information while addressing a targeted legal and medical concern: understanding the factors that determine qualification for compensation following Reglan use and subsequent tardive dyskinesia diagnosis.

Find Out If You Qualify for Compensation →

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a dopamine receptor blocking agent prescribed for conditions such as diabetic gastroparesis and symptomatic gastroesophageal reflux. Its use carries a well-documented risk of tardive dyskinesia (TD), a potentially irreversible hyperkinetic movement disorder. The U.S. Food and Drug Administration (FDA) has mandated a boxed warning on Reglan’s label, stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning further specifies that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks; if longer use is unavoidable, routine monitoring for signs and symptoms of TD is required (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, often disfiguring movements of the face, tongue, trunk, and extremities. The condition is caused by exposure to dopamine receptor blocking agents, including metoclopramide (https://pubmed.ncbi.nlm.nih.gov/29433808/). Although TD was initially associated primarily with typical antipsychotics, the incidence is likely similar with atypical antipsychotics and antiemetics such as metoclopramide (https://pubmed.ncbi.nlm.nih.gov/29433808/). Increased prescribing of these agents, along with low rates of remission, has contributed to a rising prevalence of TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). The FDA-approved label for Reglan notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Risk Factors and Mechanisms

The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the brain, which can lead to supersensitivity of dopamine receptors and subsequent hyperkinetic movements. The risk of developing TD from metoclopramide is estimated to be low, in the range of 0.1% per 1000 patient years, according to a review of pharmacokinetic and pharmacodynamic data (https://pubmed.ncbi.nlm.nih.gov/31050085/). This figure is far below previously estimated risks of 1% to 10% suggested in treatment guidelines by regulatory authorities (https://pubmed.ncbi.nlm.nih.gov/31050085/). High-risk groups include elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). From a risk perspective, the adequacy of warnings regarding Reglan and TD is a critical consideration. The FDA boxed warning explicitly states that metoclopramide can cause TD, that the risk increases with treatment duration and cumulative dosage, and that the drug should be used for the shortest duration possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label also advises immediate discontinuation of Reglan in patients who develop signs or symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, cases of TD have occurred, often after prolonged use beyond recommended durations. The timeline between exposure and documented harm can vary; TD may develop after months or years of treatment, and symptoms may persist or become permanent even after drug cessation.

Settlement Criteria for Affected Patients

Settlement-related considerations for affected patients hinge on several factors. First, the presence of a documented diagnosis of TD following Reglan use is essential. Second, the duration and cumulative dosage of Reglan exposure must be established, as the risk is dose- and time-dependent. Third, the adequacy of warnings provided to the patient and prescriber may be examined; if warnings were insufficient or not communicated, liability may be stronger. Fourth, the timeline between exposure and onset of symptoms is relevant, as delayed recognition can complicate claims. Patients who developed TD after using Reglan for longer than 12 weeks, or who were not monitored for signs of TD, may have stronger grounds for settlement. Additionally, the availability of FDA-approved treatments for TD, such as VMAT2 inhibitors, may influence settlement amounts by providing a basis for medical expenses (https://pubmed.ncbi.nlm.nih.gov/29433808/). In summary, Reglan use carries a known risk of tardive dyskinesia, with the risk increasing with longer treatment duration and higher cumulative doses. The FDA boxed warning provides clear guidance on limiting use and monitoring for symptoms. However, cases of TD continue to occur, particularly in high-risk populations. Settlement criteria for affected patients typically require evidence of prolonged Reglan exposure, a confirmed TD diagnosis, and a timeline linking the drug to the harm. The adequacy of warnings and the patient’s risk factors are also key considerations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Reglan and how is it linked to tardive dyskinesia?

Reglan (metoclopramide) is a dopamine receptor blocking agent used for conditions like diabetic gastroparesis and GERD. It carries a known risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA boxed warning states that metoclopramide can cause TD, with risk increasing with treatment duration and cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the key criteria for a Reglan TD settlement?

Key criteria include a documented TD diagnosis following Reglan use, evidence of prolonged exposure (often beyond 12 weeks) and cumulative dosage, a timeline linking the drug to the harm, and assessment of warning adequacy. High-risk factors like age, diabetes, or concomitant antipsychotic use may also be considered.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.